A Randomized, Controlled, Dose-Escalation Pilot Study to Assess the Safety and Efficacy of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Diabetic Nephropathy and Type 2 Diabetes

Trial Profile

A Randomized, Controlled, Dose-Escalation Pilot Study to Assess the Safety and Efficacy of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Diabetic Nephropathy and Type 2 Diabetes

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Rexlemestrocel-L (Primary)
  • Indications Diabetic nephropathies
  • Focus Adverse reactions
  • Sponsors Mesoblast
  • Most Recent Events

    • 06 Oct 2016 Results published in the Mesoblast Media Release.
    • 06 Oct 2016 Primary endpoint has been met. (Decline or change in glomerular filtration rate (GFR)), as reported by a Mesoblast media release.
    • 06 Oct 2016 Results from this trial were published in the current issue of the peer-reviewed journal EBioMedicine, as reported by a Mesoblast media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top